- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04713917
Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment (EPIONE-01)
Prospective Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment : a Randomized Multicenter Controlled Trial
Many studies have shown that locoregional treatment (surgery, radiotherapy) and systemic treatment (endocrine therapy and chemotherapy) for breast cancer (BC) may impact sexuality by causing physical and/or psychological damages.
Approximately 50-75 % of BC survivors suffer from vulvovaginal atrophy (VVA). The earliest symptoms of VVA are decreased vaginal lubrication, followed by other vaginal and urinary symptoms, such as burning, itching, bleeding, leucorrhoea, dyspareunia and dysuria symptoms. Various surveys have shown that VVA symptoms lead to female sexual disorder and on their partners through sexual unsatisfactory. However, it appears that sexuality is a little discussed topic during the follow-up of BC survivors. Most of patients relate a poor satisfaction with information and counselling related to sexuality and vaginal health, which are denied by many practitioners.
Patients treated for BC cannot find relief in hormonal replacement therapy (HRT), which is considered the gold standard treatment for VVA symptoms. The usual treatments for these women are topics such as ovula or gel (lubricant, hyaluronic acid (HA)…) with however, a short term effect even when these topics are applied regularly and correctly during at least 2 to 3/weeks.In the literature, there is a significant impact on VVA at one month but later data are lacking . Moreover, patients' compliance and daily application are paramount of importance for efficacy that could disappear when the treatment is stopped.
No randomized controlled trial has compared this treatment to innovative strategies. In this context, it is important to establish management strategies for VVA and sexual disorder after BC.
Our objective is to assess prevalence rate of VVA among breast cancer survivors after the loco regional treatment and chemotherapy, and to compare the efficacy of innovative treatments namely, new biophysical inductor (Laser CO2) and chemical bio inductor (Hyaluronic acid injections) treatments to the efficacy of standard non-hormonal topic treatment for improving the VVA and the quality of sexual life on a long-term.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An open-label multicentre controlled trial randomized in 3 parallel groups (1:1:1) to assess the one-year superiority of bio physical inductor (C02 laser, D0 and M6, group laser) compared to the standard treatment currently recommended (Mucogyne, 2 times a week for one year, control group) in the one hand, and of chemical bio inductor (Desirial, injection of 1 mL of hyaluronic acid in the first 3 cm of the vaginal walls, D0 and M6, HA injection group) compared to the control group in the other hand in BC survivors with VVA, with blinded primary endpoint assessment.
The use of these innovative treatments (lasers and injections) for Vulvovaginal atrophy based on the bio induction and the regenerative medicine could improve the quality of the vaginal mucosa after breast cancer therapy and could be a new strategy for these women who cannot benefit from Hormone Replacement Therapy (HRT). The benefits expected are the improvement of the quality of vulvo-vaginal mucosa and the improvement of the sexual quality of life of the patient.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Barbara HERSANT, MD
- Phone Number: +33 1 49 81 45 33
- Email: barbara.hersant@aphp.fr
Study Contact Backup
- Name: Yazid BELKACEMI, MD, PhD
- Phone Number: +33 1 49 81 45 22
- Email: yazid.belkacemi@aphp.fr
Study Locations
-
-
-
Créteil, France, 94000
- Recruiting
- Henri-Mondor Hospital
-
Contact:
- YAZID BELKACEMI
- Phone Number: 01 49 81 45 22
- Email: yazid.belkacemi@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women who present VVA with a vaginal health index < 15
- 18 years ≤ Age ≤ 75 years
- Patient with non-metastatic breast cancer
- End of loco-regional treatments (surgery+/- radiotherapy) and chemotherapy for 6 months
- Patients with no psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Written consent
- Affiliation to a social security system
Exclusion Criteria:
- Pregnant or breastfeeding woman (A Urinary bHCG will be performed for no menopausal women)
- Vulvo vaginal area showing signs of clinical inflammation and/or viral infection (e.g.: Papilloma, Herpes), bacterial, fungal.
- Abnormal vaginal smear within 3 years before inclusion
- History of vulvo vaginal cancer
- History of Papilloma virus
- History of vaginal herpes
- Use of topical hyaluronic acid application in the month before inclusion
- History of allergy to HA
- Hypersensitivity to the components of Mucogyne®, and Desirial®
- Patients with tendency to develop hypertrophic scars
- No contraception, or no efficient contraception(for women with non-menopausal status)
- Patients under legal protection
- Prisoners
- Participation to another interventional study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Gel Group
Two applications of HA gel (Mucogyne®) per week during one year.
|
Vaginal gel based on HA with liposomal structure applicated 2 times a week
|
Experimental: Laser Group
Laser CO2 for vulvovaginal area during 2 sessions (15 min) at visits D0 and M6.
|
The laser energy delivered along the vaginal wall heats the tissue without damaging it.
|
Experimental: HA Injection Group
Injection of 1 mL of HA at D0 and M6 (DESIRIAL®).
|
HA injection performed under the mucosae (2-3mm in depth) following one injection point every 5mm on the 3 first cm of the vagina and on the posterior part of the introitus.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of women free from vulvo-vaginal atrophy on the basis of a vaginal health index (VHI) ≥ 15.
Time Frame: at 12 months
|
at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparisons among groups of VHI score (absolute and relative changes in the VHI)
Time Frame: Day 0 to 12 months
|
Day 0 to 12 months
|
Female Sexual Distress (FSD) SCALE
Time Frame: Day 0 to 12 months
|
Day 0 to 12 months
|
Evaluation of the pain during treatment (Visual Analogue Scale (EVA))
Time Frame: Day 0 to 12 months
|
Day 0 to 12 months
|
Rate of adverse effects
Time Frame: Day 0 to 12 months
|
Day 0 to 12 months
|
compliance in the control treatment by the count of forgetfulness during the treatment per topical gel
Time Frame: Day 0 to 12 months
|
Day 0 to 12 months
|
Collaborators and Investigators
Investigators
- Study Director: Barbara HERSANT, MD, Assistance Publique - Hôpitaux de Paris
- Study Director: Yazid BELKACEMI, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P170927J
- 2018-A01678-47 (Other Identifier: N° IDRCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Hyaluronique Acid Gel
-
Assistance Publique Hopitaux De MarseilleCompletedAntro-pyloric and/or Duodenal Benign or Malignant ObstructionsFrance
-
Leeds Beckett UniversityNot yet recruitingRheumatoid Arthritis | Muscle Atrophy
-
Government Dental College and Research Institute...Completed
-
LEO PharmaBayerCompletedPerioral DermatitisGermany
-
Taro Pharmaceuticals USACompleted
-
LEO PharmaBayerCompletedSeborrheic Dermatitis on the FaceGermany
-
Medical University of ViennaRecruiting
-
Rabin Medical CenterUnknownLabor, First Stage | Labor, Second StageIsrael
-
Institute of Dental Sciences, Bareilly, Uttar Pradesh...UnknownCHRONIC PERIODONTITIS